Do PARP inhibitors improve survival for patients with BRCA-mutated Ovarian Cancer?
PARP inhibitors are a type of targeted therapy that blocks a DNA repair enzyme, making them especially effective in cancers with BRCA mutations. For patients with BRCA-mutated ovarian cancer, PARP inhibitors have become a key part of treatment, particularly as maintenance therapy after chemotherapy. Clinical trials show they can delay cancer growth and, in some cases, extend overall survival.
What the research says
The SOLO1 trial, a landmark phase 3 study, found that maintenance olaparib (a PARP inhibitor) significantly improved progression-free survival in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After 5 years of follow-up, the benefit persisted, with a median progression-free survival not reached in the olaparib group versus 13.8 months with placebo 9. Another trial, OReO/ENGOT-ov38, showed that even in patients who had previously received a PARP inhibitor, rechallenging with olaparib improved progression-free survival in the BRCA-mutated cohort (median 4.3 vs. 2.8 months) 10. A 2025 review confirms that PARP inhibitors have markedly improved progression-free survival in BRCA-mutated ovarian cancer 11. Additionally, combination strategies with other agents are being explored to overcome resistance, as noted in a review on DNA damage response inhibitors 2. While most evidence focuses on progression-free survival, some studies also report overall survival benefits, though data are still maturing.
What to ask your doctor
- Based on my BRCA mutation status, would a PARP inhibitor be appropriate for my treatment plan?
- What are the potential side effects of PARP inhibitors, and how can they be managed?
- If I have already received a PARP inhibitor, is there evidence for using it again (rechallenge) in my case?
- Are there any ongoing clinical trials combining PARP inhibitors with other therapies for ovarian cancer?
- How does my response to platinum-based chemotherapy affect the likelihood of benefit from a PARP inhibitor?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.